NDLI: Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.

Please wait, while we are loading the content...

A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.

Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.

Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.

Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.

Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.

Administration of anticancer drugs: exposure in hospital nurses.

Adverse event management in mass drug administration for neglected tropical diseases.

A population pharmacokinetic analysis of the influence of nutritional status of digoxin in hospitalized Korean patients.

Trans fatty acids: are its cardiovascular risks fully appreciated?

FDA's proposed ban on trans fats: How do the costs and benefits stack up?

Overview of local, state, and national government legislation restricting trans fats.

First time compliance inspections to evaluate an artificial trans fat ban in Nassau County.

Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype.

From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.

Year: 2014 Volume: 36 Issue: 2

Year: 2014 Volume: 36 Issue: 1

Year: 2013 Volume: 35

Year: 2012 Volume: 34

Year: 2011 Volume: 33

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Cipriani, Paola Ruscitti, Piero Carubbi, Francesco Liakouli, Vasiliki Giacomelli, Roberto
Description	Author Affiliation: Cipriani P ( Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy. Electronic address: paola.cipriani@cc.univaq.it.); Ruscitti P ( Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy.); Carubbi F ( Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy.); Liakouli V ( Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy.); Giacomelli R ( Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy.)
Abstract	BACKGROUND: Methotrexate (MTX) is currently considered the drug of choice, among the disease-modifying antirheumatic drugs, for the treatment of rheumatoid arthritis (RA) because of its favorable risk/benefit ratio, good safety profile, and low costs. Despite MTX's widespread use and large experience accumulated over the many years since its introduction into clinical practice, specific guidelines have not been published. OBJECTIVE: We report here the available research regarding the optimal dosage and route of MTX administration. METHODS: MEDLINE and the Cochrane Library were systematically searched for articles published between 1990 and 2013, using terms related to RA and MTX. The search was conducted by using both MeSH terms and free text. The references of the retrieved studies were also screened manually for additional articles. RESULTS: For the treatment of rheumatic diseases, the antimetabolite drug MTX can be administered weekly by different routes: oral, subcutaneous, or intramuscular. One of the goals of treatment is to minimize acute and chronic toxicity. A starting dose of 15 mg/week orally, escalating to 25 to 30 mg/week or the highest tolerable dose (with a subsequent switch to parenteral administration in cases of insufficient response), seems to be the optimal evidence-based strategy for MTX treatment of RA. Oral MTX is widely preferred because of its low costs and patient preferences; the bioavailability of parenteral MTX is higher, however. This is supported by data from observational studies, in which patients switching from parenteral to oral MTX at an equal dose had disease exacerbations. In several trials, the subcutaneous formulation of MTX was considered, by both physicians and patients, to be more advantageous in terms of discomfort and compliance. In addition, a significant proportion of patients reported that this formulation led to greater independence, with a resulting improvement in quality of life. CONCLUSIONS: Although MTX treatment can be initiated by using the oral administration route, parenteral administration of MTX is indicated in those patients with poor compliance toward the oral form. The subcutaneous route seems to be more effective than the oral route for MTX administration based on the results of several studies, and this route may be preferred because of better usability and absence of pain at the infusion site.
File Format	HTM / HTML
ISSN	01492918
Issue Number	3
Volume Number	36
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2014-03-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Antirheumatic Agents Therapeutic Use Arthritis, Rheumatoid Drug Therapy Drug Administration Routes Methotrexate Administration & Dosage Administration, Oral Biological Availability Humans Infusions, Parenteral Injections, Intramuscular Injections, Subcutaneous Adverse Effects Quality Of Life Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review.

Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis.

Methotrexat : Vorteile der subkutanen Applikationsform.

Lokale bivirkninger ved parenteral administrasjon av legemidler.

Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration

Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.

Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.

Similar Documents

Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review.

Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis.

Methotrexat : Vorteile der subkutanen Applikationsform.

Lokale bivirkninger ved parenteral administrasjon av legemidler.

Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration

Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.

Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.